Investment Summary |
|
|---|---|
| Date | 2020-05-11 |
| Target | ADC Therapeutics |
| Sector | Life Science |
| Sellers(s) |
Auven Therapeutics
MedImmune |
| Deal Type | IPO |
SEARCH BY
Auven Therapeutics is a private equity firm focused on investing in life science companies. Auven looks to acquire controlling ownership in promising therapeutic products or platforms and develop programs to selling them as clinically and commercially validated products to established pharmaceutical companies. Auven Therapeutics was established in 2007 and is headquartered in St. Thomas, US Virgin Islands.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 4 |
| Sector: Life Science M&A | 3 of 3 |
| Type: IPO M&A Deals | 1 of 1 |
| Country: Switzerland M&A | 1 of 1 |
| Year: 2020 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-10-26 |
Ocular Technologies Sarl
Lyme Park, South Africa Ocular Technologies Sarl is a specialist enterprise communications company and turnkey services provider. The company has made its mark at the forefront of the industry as a preferred partner for large-scale corporates, SMMEs and government affiliates alike. |
Sell | $40M |
| Category | Company |
|---|---|
| Founded | 1988 |
| Sector | Medical Products |
| Employees | 2,000 |
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 2,000 employees worldwide, MedImmune is headquartered in Maryland.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: IPO M&A Deals | 1 of 1 |
| Country: Switzerland M&A | 1 of 1 |
| Year: 2020 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-10-15 |
Spirogen
London, United Kingdom The Spirogen group was founded in 2001 as a spin-out from several institutions including University College London and with partial funding by Cancer Research UK. It is majority owned by Auven Therapeutics. It has developed a novel class of highly potent cytotoxic warheads based on its proprietary pyrrolobenzodiazepines (PBDs), DNA minor groove binding agents, which bind and cross-link specific sites of DNA of the cancer cell. |
Buy | $240M |
